

attach paper no. 7

PATENT
Our Docket: P31 8756

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
TULLIS
Serial No.: 07/633,453
Filed: December 20, 1990
For: OLIGONUCLEOTIDE
THERAPEUTIC AGENT AND
METHODS OF MAKING SAME

Group Art Unit: 185
Examiner: J. Martinell

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

BEST AVAILABLE COPY

COMMUNICATION

Sir:

The Examiner requested a proposed amendment be forwarded for his review prior to the interview scheduled with Applicant's attorney, Cathryn Campbell, during the week of October 14, 1991. Therefore, transmitted herewith is a proposed amendment to the Office Action mailed on August 6, 1991, for the above-identified application.

Respectfully submitted,

Date: October 9, 1991

Theresa A. Brown
Theresa A. Brown
Registration No. 32,547
Telephone: (619) 535-9001
Facsimile: (619) 535-8949

PRETTY, SCHROEDER,
BRUEGGEMANN & CLARK
444 South Flower Street
Suite 2000
Los Angeles, California 90071

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that these 4 papers are being facsimile transmitted to the Patent and Trademark Office on date shown below:

STEPHEN E. NETTER

Sept E. B. 10/10/91

OCT 10 1991

DIRECTOR
GROUP

J.C.F.

DRAFT

PATENT
Our Docket: P31 8756

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
TULLIS

Serial No.: 07/633,453

Filed: December 20, 1990

For: OLIGONUCLEOTIDE
THERAPEUTIC AGENT AND
METHODS OF MAKING SAME

Group Art Unit: 185

Examiner: J. Martinelli

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PROPOSED RESPONSE TO OFFICE ACTION

Sir:

In response to the Office Action mailed on August 6, 1991, Applicant requests entry of the amendments and consideration of the remarks set forth below.

PROPOSED AMENDMENTS

In the Claims:

53. (amended) A method of developing oligodeoxyribonucleotide therapeutic agents for use in in vivo inhibition of the synthesis of one or more targeted proteins in a cell without substantially inhibiting the synthesis of non-targeted proteins, comprising the steps of:

determining the base sequence of an organism's messenger ribonucleic acid, said base sequence coding for at least a portion of said protein targeted for inhibition;

synthesizing an oligodeoxyribonucleotide, the nucleotide sequence of which is substantially complementary to at least a portion of said base sequence and capable of hybridization with said messenger ribonucleic acid base sequence

BEST AVAILABLE COPY